Cargando…

Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?

BACKGROUND: This retrospective study evaluated modified three-dose melarsomine treatment protocols in a shelter setting and compared them to the American Heartworm Society (AHS)-recommended protocol. METHODS: As compared with the AHS protocol, the shelter protocols utilized doxycycline 10 mg/kg once...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Karen Ann, Jacobson, Linda Susan, Lacaden, Aveline Baldasan, Harrison, Kelly Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142153/
https://www.ncbi.nlm.nih.gov/pubmed/37106346
http://dx.doi.org/10.1186/s13071-022-05625-9
_version_ 1785033546573807616
author Ward, Karen Ann
Jacobson, Linda Susan
Lacaden, Aveline Baldasan
Harrison, Kelly Ann
author_facet Ward, Karen Ann
Jacobson, Linda Susan
Lacaden, Aveline Baldasan
Harrison, Kelly Ann
author_sort Ward, Karen Ann
collection PubMed
description BACKGROUND: This retrospective study evaluated modified three-dose melarsomine treatment protocols in a shelter setting and compared them to the American Heartworm Society (AHS)-recommended protocol. METHODS: As compared with the AHS protocol, the shelter protocols utilized doxycycline 10 mg/kg once daily (SID) or twice daily (BID), and varied the time from initiation of doxycycline (day 1) to the first melarsomine injection (M1). Dogs were retrospectively grouped based on the shelter’s current protocol (M1 on day 14; Group A) and the AHS protocol (M1 on day 60; Group C), allowing a week on either side of the target M1 day. Treatments that fell outside these ranges formed two additional treatment groups (Groups B and D). Respiratory complications were defined as respiratory signs requiring additional treatment, and were statistically compared for Groups A and C. New respiratory signs and gastrointestinal (GI) signs were compared between dogs receiving SID or BID doxycycline. RESULTS: One hundred fifty-seven dogs with asymptomatic or mild heartworm disease at presentation were included. All dogs survived to discharge. There was no statistically significant difference between Groups A (n = 79) and C (n = 27) for new respiratory signs post-melarsomine (P = 0.73). The time to M1 for 14 dogs that developed new respiratory signs was a median of 19 days, compared with 22 days for 143 dogs without new respiratory signs (P = 0.2). Respiratory complications post-melarsomine were uncommon. New respiratory signs post-melarsomine occurred in 10/109 (9.2%) dogs receiving SID doxycycline and 4/48 (8.3%) dogs receiving BID doxycycline (P > 0.999). GI signs prior to M1 were recorded for 40/109 (36.7%) dogs receiving SID doxycycline and 25/48 (52.1%) receiving BID doxycycline (P = 0.08). Forty-four follow-up antigen test results were available; all tests performed > 3 months after the third melarsomine injection were negative. CONCLUSIONS: This study provided support for initiating melarsomine after 14 days of doxycycline and for a lower doxycycline dose. Shorter and less expensive treatment protocols can increase lifesaving capacity and improve quality of life for shelter dogs by reducing the duration of exercise restriction and length of stay. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10142153
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101421532023-04-29 Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less? Ward, Karen Ann Jacobson, Linda Susan Lacaden, Aveline Baldasan Harrison, Kelly Ann Parasit Vectors Research BACKGROUND: This retrospective study evaluated modified three-dose melarsomine treatment protocols in a shelter setting and compared them to the American Heartworm Society (AHS)-recommended protocol. METHODS: As compared with the AHS protocol, the shelter protocols utilized doxycycline 10 mg/kg once daily (SID) or twice daily (BID), and varied the time from initiation of doxycycline (day 1) to the first melarsomine injection (M1). Dogs were retrospectively grouped based on the shelter’s current protocol (M1 on day 14; Group A) and the AHS protocol (M1 on day 60; Group C), allowing a week on either side of the target M1 day. Treatments that fell outside these ranges formed two additional treatment groups (Groups B and D). Respiratory complications were defined as respiratory signs requiring additional treatment, and were statistically compared for Groups A and C. New respiratory signs and gastrointestinal (GI) signs were compared between dogs receiving SID or BID doxycycline. RESULTS: One hundred fifty-seven dogs with asymptomatic or mild heartworm disease at presentation were included. All dogs survived to discharge. There was no statistically significant difference between Groups A (n = 79) and C (n = 27) for new respiratory signs post-melarsomine (P = 0.73). The time to M1 for 14 dogs that developed new respiratory signs was a median of 19 days, compared with 22 days for 143 dogs without new respiratory signs (P = 0.2). Respiratory complications post-melarsomine were uncommon. New respiratory signs post-melarsomine occurred in 10/109 (9.2%) dogs receiving SID doxycycline and 4/48 (8.3%) dogs receiving BID doxycycline (P > 0.999). GI signs prior to M1 were recorded for 40/109 (36.7%) dogs receiving SID doxycycline and 25/48 (52.1%) receiving BID doxycycline (P = 0.08). Forty-four follow-up antigen test results were available; all tests performed > 3 months after the third melarsomine injection were negative. CONCLUSIONS: This study provided support for initiating melarsomine after 14 days of doxycycline and for a lower doxycycline dose. Shorter and less expensive treatment protocols can increase lifesaving capacity and improve quality of life for shelter dogs by reducing the duration of exercise restriction and length of stay. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2023-04-28 /pmc/articles/PMC10142153/ /pubmed/37106346 http://dx.doi.org/10.1186/s13071-022-05625-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ward, Karen Ann
Jacobson, Linda Susan
Lacaden, Aveline Baldasan
Harrison, Kelly Ann
Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
title Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
title_full Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
title_fullStr Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
title_full_unstemmed Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
title_short Further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
title_sort further variation of the adulticide protocol for the treatment of canine heartworm infection: can it be even shorter and cost less?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142153/
https://www.ncbi.nlm.nih.gov/pubmed/37106346
http://dx.doi.org/10.1186/s13071-022-05625-9
work_keys_str_mv AT wardkarenann furthervariationoftheadulticideprotocolforthetreatmentofcanineheartworminfectioncanitbeevenshorterandcostless
AT jacobsonlindasusan furthervariationoftheadulticideprotocolforthetreatmentofcanineheartworminfectioncanitbeevenshorterandcostless
AT lacadenavelinebaldasan furthervariationoftheadulticideprotocolforthetreatmentofcanineheartworminfectioncanitbeevenshorterandcostless
AT harrisonkellyann furthervariationoftheadulticideprotocolforthetreatmentofcanineheartworminfectioncanitbeevenshorterandcostless